@prefix dct: .
@prefix biolink: .
@prefix infores: .
@prefix np: .
@prefix npx: .
@prefix orcid: .
@prefix pav: .
@prefix prov: .
@prefix rdf: .
@prefix rdfs: .
@prefix sub: .
@prefix tao: .
@prefix this: .
@prefix umls: .
@prefix xsd: .
sub:Head {
this: np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:pubinfo;
a np:Nanopublication .
}
sub:assertion {
umls:C0011810 a biolink:ChemicalEntity;
rdfs:label "Dextroamphetamine sulfate";
biolink:category "biolink:ChemicalEntity";
biolink:id "UMLS:C0011810" .
a biolink:DiseaseOrPhenotypicFeature;
rdfs:label "Attention Deficit Disorder with Hyperactivity";
biolink:category "biolink:DiseaseOrPhenotypicFeature";
biolink:id "MONDO:0005302" .
sub:_na8e63c0967774770aa886e0901005a8ab2 rdf:object ;
rdf:predicate biolink:treats;
rdf:subject umls:C0011810;
a biolink:Association;
biolink:aggregator_knowledge_source infores:knowledge-collaboratory;
biolink:category "biolink:Association";
biolink:id "collaboratory:UMLS:C0011810-biolink:treats-MONDO:0005302";
biolink:publications .
a biolink:Publication;
biolink:category "biolink:Publication";
biolink:id "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bed3c03f4-2829-423f-a595-dc09c9cc0e40" .
infores:knowledge-collaboratory a biolink:InformationResource;
biolink:category "biolink:InformationResource";
biolink:id "infores:knowledge-collaboratory" .
}
sub:provenance {
sub:_na8e63c0967774770aa886e0901005a8ab4 tao:begins_at "67"^^xsd:integer;
tao:denotes ;
tao:ends_at "112"^^xsd:integer;
tao:has_value "Attention Deficit Disorder with Hyperactivity";
tao:part_of sub:document;
a tao:text_span .
sub:_na8e63c0967774770aa886e0901005a8ab6 tao:begins_at "0"^^xsd:integer;
tao:denotes umls:C0011810;
tao:ends_at "25"^^xsd:integer;
tao:has_value "Dextroamphetamine sulfate";
tao:part_of sub:document;
a tao:text_span .
sub:assertion prov:generatedAtTime "2023-02-27T16:53:35.642515"^^xsd:dateTime;
prov:hadPrimarySource ;
prov:wasAttributedTo orcid:0000-0002-1501-1082 .
sub:document tao:has_value "Dextroamphetamine sulfate tablets are indicated in: Narcolepsy and Attention Deficit Disorder with Hyperactivity: As an integral part of a total treatment program that typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in pediatric patients (ages 3 years to 16 years)";
a tao:document_text;
rdfs:seeAlso .
}
sub:pubinfo {
sub:sig npx:hasAlgorithm "RSA";
npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQD3RHyHR7WWKBYevw1qK86B6RVzI7oKlvghqXvbpOAX1KueDE6Itru34HRhrVy4OMLCRQWBE3VXktKdbgOxD3vC4cIxz5LX+XOgGWzv5WKSjOfXu/yIeJrzsuIkyHvw7/tToGrE0itJ1wGylJv+YieizmGvNiUHhP0J0+YFMNnvewIDAQAB";
npx:hasSignature "xPLfAYF36ov6tLHrPAI9T0RjKCNtHIubj3WrIissgchN+/CtvpptDPAZRG4O+XThEVTja1ap+pDk8uyze+g4kGm420KC3mWEZ2117na3v9Ow1O55/TRyYJH9Vq2IRajHORO4zNy5c5GAmbuFzk2S3WujAlvVMeaDxybjcq4d164=";
npx:hasSignatureTarget this: .
this: dct:conformsTo biolink:;
prov:generatedAtTime "2023-02-27T16:53:35.642515"^^xsd:dateTime;
prov:wasAttributedTo orcid:0000-0002-1501-1082 .
biolink: pav:version "3.1.0" .
}